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Abstract

MORE ONLINE

Background and Objectives
This study aims to quantify microglial activation in individuals with Alzheimer disease (AD) using
the 18-kDa translocator protein (TSPO) PET imaging in the hippocampus and precuneus, the 2
AD-vulnerable regions, and to evaluate the association of baseline neuroinﬂammation with
amyloidosis, tau, and longitudinal cognitive decline.

Criteria for rating
therapeutic and diagnostic
studies
NPub.org/coe

Class of Evidence

Methods
Twenty-four participants from the Knight Alzheimer Disease Research Center (Knight ADRC)
were enrolled and classiﬁed into stable cognitively normal, progressor, and symptomatic AD
groups based on clinical dementia rating (CDR) at 2 or more clinical assessments. The baseline
TSPO radiotracer [11C]PK11195 was used to image microglial activation. Baseline CSF
concentrations of Aβ42, Aβ42/Aβ40 ratio, tau phosphorylated at position 181 (p-tau181), and
total tau (t-tau) were measured. Clinical and cognitive decline were examined with longitudinal
CDR and cognitive composite scores (Global and Knight ADRC-Preclinical Alzheimer Cognitive Composite [Knight ADRC-PACC] Score).
Results
Participants in the progressor and symptomatic AD groups had signiﬁcantly elevated [11C]
PK11195 standard uptake value ratios (SUVRs) in the hippocampus but not in the precuneus
region. In the subcohort with CSF biomarkers (16 of the 24), signiﬁcant negative correlations
between CSF Aβ42 or Aβ42/Aβ40 and [11C]PK11195 SUVR were observed in the hippocampus and precuneus. No correlations were observed between [11C]PK11195 SUVR and
CSF p-tau181 or t-tau at baseline in those regions. Higher baseline [11C]PK11195 SUVR
averaged in the whole cortical regions predicted longitudinal decline on cognitive tests.
Discussion
Microglial activation is increased in individuals with brain amyloidosis and predicts worsening
cognition in AD.
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Glossary
AD = Alzheimer disease; Aβ = β-amyloid; CDR = clinical dementia rating; CDR-SB = CDR Sum of Boxes; Knight ADRCPACC = Knight Alzheimer Disease Research Center Preclinical Alzheimer Composite Score; MMSE = Mini-Mental State
Examination; MPRAGE = magnetization-prepared rapid acquisition gradient echo; PET = positron emission tomography; SB =
sum of boxes; SUVR = standard uptake value ratio; TSPO = 18 kDa translocator protein.

Classification of Evidence
This study provides Class II evidence that in patients with AD, higher baseline [11C]PK11195 SUVR averaged in the whole
cortical regions was associated with longitudinal decline on cognitive tests.

The characteristic pathology of Alzheimer disease (AD) is the
deposition of extracellular β-amyloid (Aβ) plaques and intracellular tau ﬁbrils. Amyloid plaques and tau tangles are
believed to initiate a cascade of pathology that includes neuroinﬂammation,1 synaptic dysfunction, and neuronal death,
resulting in dementia. There is extensive literature documenting
a microglial-mediated inﬂammatory response in AD.2 Multiple
longitudinal studies demonstrate that inﬂammation and microglial activation begin early in AD, many years before dementia
onset.3,4 It is also notable that microglia play a key role in neuroinﬂammatory response not only to amyloid deposition but also
to tau accumulation in AD brains.5
Despite the association of neuroinﬂammation with AD, the
exact role of inﬂammation in AD remains unclear. It has been
suggested that in the early stages of AD, the initial microglial
activation may serve a protective role trying to clear amyloid.6
In the later stages of AD, when clearance fails, microglia could
play a detrimental role by producing proinﬂammatory cytokines, leading to progressive neurodegeneration.7 Furthermore, the relationship between neuroinﬂammation,
amyloidosis, and cognitive decline is still unclear and warrants
further investigation. The hippocampus and precuneus are
involved in the earliest neuropathologic changes in AD and
are sensitive to AD pathologies of amyloid and tau.8-11 Focusing analyses on those regions would shed light on the
relationships among the neuroinﬂammation, amyloid, tau,
and cognition.
After activation, microglia proliferate and express a series of
genes for proinﬂammatory cytokines and certain receptors on
their surface, including the 18-kDa translocator protein
(TSPO). The advent of PET radioligands that bind the
microglial protein, TSPO, including [11C]PK11195, allows
assessment of activated microglia in many neurologic disorders, including AD.12 The aim of this study was to measure
microglial activation with [11C]PK11195 PET imaging in
cognitively normal and symptomatic AD participants and
evaluate its association with CSF biomarkers of AD pathology
and performance on cognitive tests. We hypothesized that
microglial activation would be associated with amyloidosis
and tau and would predict cognitive decline. These primary
research questions have been addressed in this study.
2

Methods
Study Participants
Study participants were enrolled in ongoing studies at the
Knight Alzheimer Disease Research Center (Knight ADRC)
at Washington University School of Medicine (St. Louis, MO).
The Human Research Protection Oﬃce at Washington University approved all studies, and written informed consent was
obtained from all participants. Both cognitively normal and
symptomatic AD participants with an age range from 55 to 90
years who underwent [11C] PK11195 PET scans were included
in this study. The cognitively normal and the symptomatic AD
participants were evaluated by the Clinical Core of the Knight
ADRC. Detailed clinical assessments of the participants were
performed in accordance with the Uniform Data Set protocol of
the National Alzheimer’s Coordinating Center.13 A clinical diagnosis of symptomatic AD, where appropriate, was made in
accordance with criteria developed by working groups from the
National Institute on Aging and the Alzheimer’s Association.14
The severity of dementia was measured with the global clinical
dementia rating (CDR),15 whereby CDR 0 is cognitively unimpaired, 0.5 is very mild dementia, 1 is mild dementia, 2 is
moderate dementia, and 3 is severe dementia. The CDR sum of
boxes (CDR-SB) was used as a more granular measure of clinical
impairment.16 The Mini-Mental State Examination (MMSE)
was also administered.17
Participants were categorized into 3 groups. Participants with
normal cognition (CDR = 0) at the time of the PET scan who
remained cognitively normal over 15 years were categorized as
stable cognitively normal. Participants who were cognitively
normal (CDR = 0) at the time of the PET scan and developed
symptomatic AD (encompassing both mild cognitive impairment due to AD and AD dementia [CDR> 0]) over an average
of 7 years of follow-up were categorized as progressors. Participants with symptomatic AD dementia at the time of PET scan
(CDR > 0) were categorized as symptomatic AD.
Standard Protocol Approvals, Registrations,
and Patient Consents
The local ethics committee of the Washington University
School of Medicine approved the study, and all participants
provided written informed consent before entering the study.
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Cognitive Measures
As a measure of cognitive performance, we used the Knight
ADRC Preclinical Alzheimer Cognitive Composite (Knight
ADRC-PACC) score and a global composite score for each
individual from the Knight ADRC cognitive battery. Consistent with previously published methods, the Knight ADRCPACC score was calculated by averaging the z score across 5
cognitive tests measuring memory, attention, and processing
speed.18 The cognitive tests were performed annually for each
individual. Speciﬁcally, the included tests were MMSE, the
Digit Symbol subtask of the Wechsler Adult Intelligence
Scale, the animal naming test, the associate learning summary
score from the Wechsler memory scale, and the free and cued
selective reminding test. The global score was derived by
averaging the z score for each individual across all common
tasks collected by the neuropsychologic battery of the
Knight ADRC. In addition to the tasks described earlier,
the global score also included the Trail A and Trail B
subtasks of the trail making test, the Boston naming test,
the summary score of the crossing-oﬀ task, the mental
control subtask of the Wechsler Memory Scale, the summary score for the S & P word ﬂuency task, the digit span
forward and backward subtasks of the revised Wechsler
Memory Scale, and the information and block subtasks of
the Weschler Adult Intelligence Scale. The resulting Knight
ADRC-PACC and global scores were used as measures of
speciﬁc and overall cognitive performance in subsequent
analyses, respectively. The baseline cognitive scores used
the cognitive assessment closest to the TSPO PET scan (all
were within 1 year).
APOE Genotyping
DNA was extracted from peripheral blood samples by standard procedures. APOE genotyping was performed as previously described.19 Individuals carrying at least 1 APOE e4
allele were classiﬁed as APOE e4 positive (APOE e4+).
CSF Collection and Analysis
CSF was collected under a standard protocol. Participants
underwent a lumbar puncture at approximately 8 AM after
overnight fasting. Twenty to 30 mL of CSF was collected in a
50-mL polypropylene tube through gravity drip using an
atraumatic Sprotte 22-gauge spinal needle. CSF was kept on
ice and centrifuged (2,000 g, 10 minutes) within 2 hours of
collection to pellet any cellular debris and then transferred to
another 50 mL tube. CSF was aliquoted in 500-μL volumes
into polypropylene tubes and stored at −80°C, as previously
described.20
Before analysis, samples were brought to room temperature.
Samples were vortexed and transferred to provided cuvettes
for analysis. Concentrations of Aβ40, Aβ42, tau phosphorylated at position 181 (p-tau181), and total tau (t-tau) were
measured by chemiluminescent enzyme immunoassay using a
fully automated platform (LUMIPULSE G1200, Fujirebio,
Malvern, PA) according to manufacturer’s speciﬁcations. A
single lot of reagents was used for all samples.
Neurology.org/NN

MRI Acquisition
Anatomic MRI was obtained on each participant with T1weighted magnetization-prepared rapid acquisition gradient
echo (MPRAGE) sequences using a Siemens Vision 1.5T
scanner or a Siemens Avanto 1.5T scanner (Siemens, Erlangen, Germany). The acquisition parameters for MPRAGE
were the following: TR, 9.7 ms; TE, 4.0 ms; inversion time, 20
ms; imaging resolution, 1 × 1 × 1.25 mm3. The T1-weighted
MRI was used for FreeSurfer parcellation21 (freesurfer.net/).
PET Acquisition and Processing
TSPO PET imaging was performed on a Siemens 962 HR +
PET scanner using the radiotracer [11C]PK11195 [1-(2chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline
carboxamide]. A 6th-minute dynamic PET scan in
3-dimensional mode (septa retracted) was acquired (24 ×
5-second frames; 9 × 20-second frames; 10 x 1-minute frames;
9 x 5-minute frames). PET scans were processed, as previously
described, using the 10- to 60-minute motion-corrected
frames for partial volume–corrected standard uptake value
ratio (SUVR).22,23 The visual check on the registration between the [11C]PK11195 SUVR maps and MPRAGE images
has been performed for each individual. Cerebellar cortex has
the lowest density of microglia24 and was used as the reference
region. Partial volume–corrected SUVRs23 were calculated for
each [11C]PK11195 scan, using the 10- to 60-minute frames
with the FreeSurfer regions and the calculated reference region of nonspeciﬁc binding in the cerebellar cortex. As the
global index to reﬂect neuroinﬂammation, a mean cortical
SUVR was calculated based on the cortical regions deﬁned by
FreeSurfer.
Regions of Interest
The hippocampus and precuneus are the 2 regions of interests
selected based on previous work ﬁnding those 2 cerebral regions as sensitive to AD pathologies of amyloid and tau.9,23
Both regions are from FreeSurfer parcellation. [11C]
PK11195 SUVRs were calculated for these regions and the
whole cortex regions.
Statistical Analysis
Nonparametric Kruskal-Wallis and the χ 2 tests were used for
comparing continuous and categorical variables of the participants’ demographics, respectively. One-way ANOVA was
used to test the group diﬀerences in [11C]PK11195 binding,
CSF biomarkers, and cognition. The Tukey honest signiﬁcant
diﬀerences were computed to perform multiple pairwise
comparison between the mean values of groups. Spearman
correlations were used to measure the strength of the associations between [11C]PK11195 SUVR and CSF biomarkers
while adjusting for eﬀects of age and sex.25 A random coeﬃcient model26 was used to examine whether the baseline
[11C]PK11195 SUVR was associated with the longitudinal
cognitive change for all participants. This statistical method
allows us to accommodate heterogeneous numbers of visits
and intervals between visits for our included participants. The
cognitive measure within 1 year of the [11C]PK11195 scan
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and all available follow-up cognitive measures for each individual were included in our statistical model. Age and sex
were included in this model as the covariates. Of importance,
time is considered a continuous variable (measured in years)
in this model, representing the interval between the baseline
cognitive assessment and each subsequent visit. Within this
model, time is treated as both a ﬁxed and random eﬀect. The
statistical model is the following:

Data Availability
All data associated with this study are present in the article or
the supplementary material. Deidentiﬁed data will be shared
on reasonable request from a qualiﬁed investigator.

Results

Cognition = β1 × time + β2 × baseline PK + β3 × time × baseline
PK + β4 × age + β5 × sex

0.05 was regarded as statistically signiﬁcant after Bonferroni
correction.

(1)

The estimate (β by type 3 sum of squares) and corresponding
p values from the interaction term, time × baseline PK, were
reported to investigate whether the baseline [11C]PK11195
SUVR predicts cognitive decline. The random coeﬃcient
model approach allows for diﬀerent intercepts and slopes for
each individual across variables of interest. This approach is
particularly useful because it accommodates the heterogeneous number of visits and intervals between visits. All statistical analyses were performed using SAS, version 9.4 (SAS
Institute Inc., Cary, NC) or R (R Core Team [2020]), and p <

Participant Demographics
Demographic data are summarized in Table 1. Individuals were
categorized into the following groups: 9 stable cognitively normal (CDR = 0 at the PET scan and follow-up 13.2 ± 3.9 years
later), 9 progressors (CDR = 0 at the PET scan and CDR > 0 at
follow-up 7.4 ± 4.8 years later), and 6 symptomatic AD (3 with
CDR = 0.5 and 3 with CDR = 1 at the PET scan). Individuals in
the progressor and AD dementia groups were signiﬁcantly older
than individuals in the stable cognitively normal group (79.7 ±
6.2, 78.2 ± 7.5, and 67.9 ± 9.8 years [mean ± SD], respectively, p
= 0.04). There were no signiﬁcant group diﬀerences in sex, years
of education, APOE e4 status, or race. CDR and CDR-SB at

Table 1 Demographic and Clinic Characteristics of the Participants
p Value

Nonconverter

Converter

AD

No.

9

9

3

3

CDR

0

0

0.5

1

CDR-SB

0.1 (0.2)

0.1 (0.2)

3.0 (2.2)

0.004

MMSE

28.3 (1.9)

29.0 (0.7)

23.5 (5.8)

0.30

Age, y

67.9 (9.8)

79.7 (6.2)

78.2 (7.5)

0.04

Female

5 (56%)

5 (56%)

4 (67%)

0.89

Education, y

14.3 (2.6)

16.0 (3.0)

13.8 (3.9)

0.32

APOE «4 carriers

4 (44%)

1 (11%)

4 (67%)

0.09

Non-Hispanic Whites

8 (89%)

9 (100%)

4 (67%)

0.17

Averaged duration of follow-ups, y

13.2 (3.9)

7.4 (4.8)

4.1 (2.9)

<0.001

Global composite score

0.11 (0.34)

0.10 (0.44)

−0.61 (0.86)

0.08

Rate of change in global composite score

−0.03 (0.02)

−0.13 (0.12)

−0.32 (0.23)

0.004

Knight ADRC-PACC score

0.05 (0.51)

0.01 (0.70)

−0.74 (0.94)

0.19

Rate of change in Knight ADRC-PACC score

−0.04 (0.04)

−0.10 (0.28)

−0.39 (0.49)

0.11

CSF measures (no.)

6

6

4

CSF Aβ42 (pg/mL)

971 (286)

672 (380)

505 (125)

0.06

CSF Aβ42/Aβ40

0.08 (0.02)

0.05 (0.02)

0.04 (0.00)

0.008

CSF p-tau181 (pg/mL)

44.1 (11.6)

74.5 (30.7)

151.1 (85.5)

0.008

CSF t-tau (pg/mL)

354 (120)

549 (198)

1,004 (573)

0.02

<0.001

Abbreviations: AD = Alzheimer disease; ADRC = Alzheimer Disease Research Center; CDR = clinical dementia rating; MMSE = Mini-Mental State Examination;
PACC = preclinical Alzheimer cognitive composite.
The mean (SD) values are provided for continuous variables; number (%) for dichotomous variables.
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baseline were higher (worse) in the symptomatic AD group
compared with the progressor and stable cognitively normal
groups (p < 0.001 and 0.004, respectively). However, there were
no signiﬁcant group diﬀerences in the MMSE, global composite
scores, or Knight ADRC-PACC scores.
[11C] PK11195 PET SUVR Maps
Representative [11C]PK11195 PET SUVR images from 1
representative individual for each group are shown in Figure 1.
Panel A is an individual from the stable cognitively normal group
(mean cortical SUVR of 0.99), panel B is from the progressor
group (SUVR 1.10), and panel C is from the symptomatic AD
group (SUVR 1.18). The mean cortical SUVRs for the groups
were as follows: stable cognitively normal, 1.10 ± 0.07 (mean ±
SD); progressor, 1.11 ± 0.10; symptomatic AD, 1.14 ± 0.15.
Although there were no signiﬁcant group diﬀerences in mean
cortical SUVR, there were signiﬁcant regional elevations of
[11C]PK11195 SUVR in the hippocampus (Figure 2A) in the
progressor and symptomatic AD groups compared with those in
the stable cognitively normal group. No group diﬀerences were
found in the precuneus (Figure 2B).

CSF Biomarkers
Of the 24 participants, 16 had available data on CSF Aβ42,
Aβ42/Aβ40, p-tau181, and t-tau within 1 year of the PET
scan. For CSF Aβ42, which is less accurate than other analytes
in detecting brain amyloidosis, there were no signiﬁcant group
diﬀerences in CSF Aβ42 by omnibus testing (Figure 3A).
Further data exploration revealed a trend toward lower CSF
Aβ42 in the symptomatic AD group compared with the stable
cognitively normal group (p = 0.06) (Figure 3A). Signiﬁcant
group diﬀerences were observed in CSF Aβ42/Aβ40,
p-tau181, and t-tau (Figures 3, B–D). The ratio of CSF Aβ42/
Aβ40, which is more sensitive to amyloidosis than CSF
Aβ42,27 was lower in the symptomatic AD group when
compared with the stable cognitively normal group (p =
0.009) (Figure 3B). CSF p-tau181 and t-tau were higher in the
symptomatic AD group when compared with those in the
stable cognitively normal group (Figures 3, C and D, p = 0.006
and p = 0.01, respectively).
The relationship between CSF biomarkers and [11C]
PK11195 SUVR was further evaluated in the entire subcohort

Figure 1 Representative [11C]PK11195 PET SUVR Maps

[11C]PK11195 PET SUVR maps of 3 representative cases from the stable cognitively normal
(A), progressor (B), and symptomatic Alzheimer
disease (C) groups.

Neurology.org/NN
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Figure 2 [11C]PK11195 PET SUVR in the Hippocampus and Precuneus Regions

Boxplots demonstrate the [11C]PK11195 PET
SUVR in 3 groups in the hippocampus (A) and
precuneus region (B). There is a significant increase in SUVR in the progressor and symptomatic Alzheimer disease groups compared
with that in the stable cognitively normal group
in the hippocampus but not in the precuneus
region. The p values were produced from the
Tukey honest significant differences test to
demonstrate the between-group differences.
Only the p values <0.05 are shown.

with CSF biomarkers using Spearman correlations adjusting
for age and sex. Signiﬁcant negative correlations were found
between CSF Aβ42 and [11C]PK11195 SUVR in the hippocampus and precuneus and the whole cortex regions as well
(Figures 4, A, E, and I). Signiﬁcant negative correlations between CSF Aβ42/Aβ40 and [11C]PK11195 SUVR were
noted in the precuneus (Figure 4J). No signiﬁcant correlations between CSF p-tau181 or t-tau and [11C]PK11195

SUVR were found. The Spearman rho (R) and p values are
shown in Figure 4.
[11C]PK11195 SUVR Predicts Cognitive Decline
The ability of TSPO PET imaging to predict future cognitive
decline was evaluated. The mean period of cognitive followup for the 3 groups (stable cognitively normal, progressor,
symptomatic AD) were 13.2 ± 3.9, 7.4 ± 4.8, and 4.1 ± 2.9,

Figure 3 CSF Measures of Amyloid and Tau

Boxplots show CSF concentrations of Aβ42,
Aβ42/Aβ40, p-tau181, and t-tau in the stable
cognitively normal, progressor, and symptomatic AD groups. There were significant decreases in the CSF Aβ42 (A) and Aβ42/Aβ40 (B)
in the Symptomatic AD group compared with
the stable cognitively normal group. There
were significant increases in CSF p-tau181 (C)
and t-tau (D) in the Symptomatic AD group
compared with those in the progressor and
stable cognitively normal groups. The p values
were produced from the Tukey honest significant differences test to demonstrate the between-group differences. Only the p values
<0.05 are labeled here. AD = Alzheimer disease.
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Figure 4 Correlations Between [11C]PK11195 SUVR and the CSF Biomarkers

Scatterplots show the significant correlations between [11C]PK11195 SUVR and CSF levels of amyloidosis (A, E, I, and J). There were no significant correlations
between [11C]PK11195 SUVR and CSF levels of p-tau181 (C, G, and K) and t-tau (D, H, and L). *, p < 0.05; adjusted by age and sex.

respectively. We used the random coeﬃcient model to investigate whether the baseline [11C]PK11195 SUVR predicts
the cognitive decline. In this study, we report the estimate (β
by type 3 sum of squares) and corresponding p values from
the interaction term: time × baseline PK from Equation 1. We
found that higher [11C]PK11195 SUVR in the whole cortex
regions (p = 0.03) predicted the cognitive decline in Knight
ADRC-PACC score, but not in global composite score
(Table 2). [11C]PK11195 SUVR in the hippocampus and
precuneus regions did not predict the decline of global and
Knight ADRC-PACC scores with p > 0.05 (Table 2). The
same statistical analysis was performed on 16 participants who
have the CSF measures. We found that higher [11C]PK11195
SUVR in the whole cortical regions predicted the cognitive
decline in the global composite score (p = 0.03) and Knight
ADRC-PACC score (p = 0.01) (eTable 1 in the supplement,
Neurology.org/NN

links.lww.com/NXI/A704). [11C]PK11195 SUVR in the
precuneus but not in the hippocampus predicted cognitive
decline in Knight ADRC-PACC score (p = 0.01) (eTable 1 in
the supplement). When considering CSF Aβ42/Aβ40 and/or
p-tau181 as covariates, [11C]PK11195 SUVR in the whole
cortical regions still predicted the cognitive decline in global
composite score and Knight ADRC-PACC score, and [11C]
PK11195 SUVR in the precuneus predicted the cognitive
decline in Knight ADRC-PACC score (eTables 2 and 3 in the
supplement).
Classification of Evidence
This study provides Class II evidence that in patients with AD,
higher baseline [11C]PK11195 SUVR averaged in the whole
cortical regions was associated with longitudinal decline on
cognitive tests.
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Table 2 Baseline [11C]PK11195 SUVR Predicts Cognitive
Decline
Global composite score

Knight ADRC-PACC score

Estimate

p Value

Estimate

p Value

Cortex

−0.74

0.11

−1.09

0.03a

Hippocampus

−0.53

0.24

−0.68

0.13

Precuneus

−0.34

0.24

−0.56

0.05

a

p < 0.05; adjusted by age and sex.

Discussion
The goal of this study was to investigate the relationships
between microglial activation measured by [11C]PK11195,
CSF biomarkers of AD, and cognitive decline. We found that
individuals categorized in the progressor and symptomatic
AD groups had higher [11C]PK11195 SUVR in the hippocampus and precuneus regions compared with the stable
cognitively normal group. Lower CSF Aβ42 and Aβ42/Aβ40,
consistent with greater brain amyloidosis, was associated with
higher [11C]PK11195 SUVR in the AD pathology–
susceptible regionsthe hippocampus and precuneus. Of interest, no signiﬁcant correlations CSF p-tau181 or t-tau were
found with [11C]PK11195 SUVR in any region. Last, [11C]
PK11195 SUVR in the overall cortical region predicted cognitive decline, as measured by the commonly used composite
score, Knight ADRC-PACC score, in AD studies.
As one of the earliest developed PET TSPO radiotracers,
[11C]PK11195 has been used to investigate the microglia
activation in AD brains.28 The lack of group diﬀerences of the
mean cortical SUVR may be attributed to the limited sample
size. However, our region-based analysis found elevated
[11C]PK11195 SUVR in the hippocampus of the progressor
and symptomatic AD groups compared with the stable cognitively normal group. The hippocampus is an important
subcortical region that is known to be severely and consistently aﬀected by AD pathologic processes and shows a
considerable shrinkage, distortion, and loss of neurons.29,30
Our previous work has demonstrated that the hippocampus
volume demonstrated higher clinical diagnostic performance
than the traditional volumetric measures for AD.8 The elevated [11C]PK11195 binding in the progressor group in this
region suggests that microglial activation may be an early
event in the pathogenesis of AD that precedes symptom
onset.7,12,31
Although lower CSF Aβ42 is well-established as a biomarker
of amyloidosis,32 the ratio of Aβ42 to Aβ40 (Aβ42/Aβ40) is
superior to Aβ42 as a biomarker of brain amyloidosis.33,34 In
this study, we investigated the relationship between microglial
activation and amyloidosis measured by both CSF Aβ42 and
Aβ42/Aβ40. We found both CSF levels of Aβ42 and Aβ42/
Aβ40 were negatively correlated with [11C]PK11195 SUVR
8

in the hippocampus and precuneus, suggesting that brain
amyloidosis and microglial activation may be linked.
Although studies have demonstrated an association of neuroinﬂammation and CSF measures of tau,4 we did not ﬁnd any
signiﬁcant correlations between [11C]PK11195 SUVR and
CSF p-tau181 or t-tau. However, not reaching the signiﬁcant
level, the trends of positive associations between [11C]
PK11195 SUVR and CSF measures of p-tau and tau in the
whole cortex and precuneus regions have been shown in
Figure 4, suggesting neuroinﬂammation could increase with
the increase in tau pathology in AD. Notably, our participants
exhibited very early AD. Accumulating evidence suggests that
neuroinﬂammation may play a neuroprotective role in early
AD, but this role may change and become pathologic in later
stages of AD.7,35 Therefore, measures of neuroinﬂammation
may vary in a nonlinear fashion across diﬀerent disease stages,
complicating studies. Large sample sizes and longitudinal
evaluations are necessary to characterize changes in neuroinﬂammation over time.
Although several previous studies have found that TSPO PET
uptake correlates inversely with cognitive measures,36,37 the
relationship between [11C]PK11195 uptake and longitudinal
cognitive decline has not been fully explored. Consistent with
a recent study that demonstrated the ability of [11C]
PK11195 to predict cognitive decline,38 we also found that
[11C]PK11195 SUVRs in the whole cortical region predicted
cognitive decline. Similar results were found on the subset
participants who have CSF measures (eTable 1 in the supplement, links.lww.com/NXI/A704). A further analysis of
whether microgliosis at baseline remains a signiﬁcant predictor of subsequent cognitive decline after including amyloid
and tau at baseline as independent predictors was performed.
[11C]PK11195 SUVRs in the whole cortical region predicting cognitive decline still remained (eTables 2 and 3 in the
supplement), suggesting microglial activation is a strong
predictor of cognitive decline.
A linear regression model was also implemented to investigate
the relationship between the baseline [11C]PK11195 binding
and the rate of change in cognitive measures. The results were
summarized in eTable 4 in the supplement, links.lww.com/
NXI/A704. Signiﬁcant negative correlations were found between the [11C]PK11195 binding and the rate of change in
Global and Knight ADRC-PACC scores in the hippocampus
region. The negative correlations between the [11C]
PK11195 binding and the rate of change in cognitive measures in the whole cortex and precuneus regions were found
but not reaching statistical signiﬁcance. Those results also
support our ﬁndings using the random coeﬃcient model that
the baseline [11C]PK11195 binding predicts cognitive decline in AD. The inverse correlation between [11C]PK11195
SUVR and the rate of change in cognitive composite score
Knight ADRC-PACC found in this study suggests that a high
level of microglial activation accelerates the cognition decline
in AD. Although associations between amyloid deposition,
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tau load, and microglial activation have been established in
both postmortem and in vivo neuroimaging studies,39,40 how
those key AD pathologies independently or jointly promote
the clinical progression of AD remains unclear. One recent
study considered the interaction of those AD pathologies
found the combined contribution of temporo-parietal tau
pathology and anterior temporal neuroinﬂammation in predicting cognitive decline in patients with symptomatic AD.38
Further studies with larger sample size are desired along this
direction.
There are several limitations in this study. First, the sample
size is small. Studies with larger sample sizes are required
to evaluate the interactions of AD pathologies in the prediction of cognitive decline. In addition, this study focused on the 2 earliest-aﬀected AD pathology-sensitive
regions—the hippocampus and precuneus. Further analysis
on the whole brain will be necessary to deepen our understanding of the spatial relationships among these AD
pathologies. Finally, CSF measures of amyloidosis and
tauopathy do not provide information on the regional distribution of AD pathology. Future studies analyzing PET
imaging of amyloid, tau, and microglial activation on the
voxel level will enable the detailed investigation of the
spatial relationships among amyloid, tau, and neuroinﬂammation in AD progression.
In summary, our results indicate a ﬁrst-generation TSPO PET
tracer developed to image microglial activation in AD. [11C]
PK11195 demonstrates higher binding both in individuals
with symptomatic AD and individuals who are cognitively
normal at baseline and progress to symptomatic AD. We
found that [11C]PK11195 binding correlated with global
amyloidosis measured by CSF biomarkers in the hippocampus and precuneus, suggesting that microglial activation is
associated with brain amyloidosis in early AD. Furthermore,
regional [11C]PK11195 binding in the overall cortical region
predicted cognitive decline in AD.
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